<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01154348</url>
  </required_header>
  <id_info>
    <org_study_id>1011N0913</org_study_id>
    <nct_id>NCT01154348</nct_id>
  </id_info>
  <brief_title>Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase 1b, Randomized, Placebo-Controlled Study to Assess the Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and pharmacokinetics of double-blind
      S-707106 alone and in combination with open-label metformin in patients with type 2 diabetes
      mellitus
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety will be evaluated by monitoring of treatment-emergent adverse events, clinical
      laboratory evaluations, vital signs, 12-lead electrocardiograms, 24-hour telemetry
      monitoring, and physical exams. Specific study withdrawal criteria during washout periods of
      metformin have been established for loss of glycemic control, i.e., glucose monitoring.
      Pharmacokinetic assessments of monotherapy cohort versus add-on therapy will be performed
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and pharmacokinetics of multiple-dose oral administration of S-707106 in fed state in patients with type 2 diabetes mellitus</measure>
    <time_frame>Adverse events will be monitored from the time of informed consent through 28 days after the last dose of study treatment. Samples for S-707106 will be collected on Days 1, 7, 10, 12, 13, and 14</time_frame>
    <description>Safety will be evaluated by monitoring of treatment-emergent adverse events, clinical laboratory evaluations, vital signs, 12-lead electrocardiograms, 24-hour telemetry monitoring and physical exams. Pharmacokinetic evaluation of monotherapy cohort versus add-on therapy will be done</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and pharmacokinetics of multiple-dose oral co-administration of S-707106 and metformin in fed state in patients with type 2 diabetes mellitus</measure>
    <time_frame>Adverse events will be monitored from the time of informed consent through 28 days after the last dose of study treatment. Samples for S-707106 collected on Days 7, 10, 12, 13, and 14. Samples for metformin collected on Days -1, 7, 10, 12, 13, and 14</time_frame>
    <description>Safety will be evaluated by monitoring of treatment-emergent adverse events, clinical laboratory evaluations, vital signs, 12-lead electrocardiograms, 24-hour telemetry monitoring and physical exams. Pharmacokinetic evalaution of monotherapy cohort versus add-on therapy will be done</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effect of multiple doses of S-707106 on pharmacokinetics of metformin</measure>
    <time_frame>On Day 14 and on day prior to initiation of dosing of S-707106</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of multiple doses of metformin on pharmacokinetics of S-707106</measure>
    <time_frame>On Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Washout period, S-707106 tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14-day washout of metformin, followed by S-707106 once daily for 14 days under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Washout, placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>14-day washout of metformin followed by placebo for S-707106 once daily for 14 days under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance, S-707106 tablet plus metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14-day maintenance of metformin, followed by S-707106 once daily plus open-label metformin twice daily for 14 days under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance, placebo plus metformin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>14-day maintenance of metformin, followed by placebo for S-707106 once daily plus open-label metformin twice daily for 14 days under fed conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-707106</intervention_name>
    <description>Tablet, taken once daily with morning meal</description>
    <arm_group_label>Washout period, S-707106 tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet, taken once daily with morning meal</description>
    <arm_group_label>Washout, placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin, S-707106 plus metformin</intervention_name>
    <description>Metformin twice daily maintenance, S-707106 tablet taken once daily with morning meal with metformin dosed twice daily</description>
    <arm_group_label>Maintenance, S-707106 tablet plus metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin, placebo plus metformin</intervention_name>
    <description>Metformin twice daily maintenance, placebo tablet taken once daily with morning meal with metformin twice daily</description>
    <arm_group_label>Maintenance, placebo plus metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index range (25.0-38 kg/m2) with type 2 diabetes mellitus receiving stable
             dose of metformin BID for the previous 60 days for glucose control

          -  Patients sterile or agree to use approved method of contraception

          -  No clinically significant abnormal tests

          -  Hemoglobin A1c level â‰¤10.5%

        Exclusion Criteria:

          -  History of clinical manifestations of significant metabolic, hepatic, renal, and
             hematological pulmonary, cardiovascular, gastrointestinal, urological, neurological,
             or psychiatric disorders other than type 2 diabetes mellitus

          -  Uncontrolled diabetes

          -  Exclusionary labs - fasting blood sugar, low hemoglobin, elevated liver function
             tests, positive result for human immunodeficiency virus, hepatitis B surface antigen,
             and anti-hepatitis C virus

          -  Low creatinine clearance

          -  History of myocardial infarction within past 90 days or other cardiovascular
             conditions

          -  Prior exposure to S-707106

          -  Treatment with investigational study drug within 30 days of study admission day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dennis Ruff, MD</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2010</study_first_submitted>
  <study_first_submitted_qc>June 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2010</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

